Every clinical trial conducted today operates under rules that trace directly back to specific historical failures and the reforms that followed them. A research administrator who understands where informed consent, IRB review, and Good Clinical Practice actually came from is better equipped to explain why a requirement exists, not just that it exists. This guide connects the milestones — most of which already have their own dedicated pages on this site — into a single narrative of how clinical trial methodology and oversight reached their current form.
This is deliberately a “how we got here” map, not a re-explanation of each milestone. For the full detail on any individual document or standard, follow the links into the relevant term or guide.
Before formal oversight: research without uniform ethical rules
Systematic human experimentation predates any of the frameworks discussed below. The 1747 scurvy trial conducted by naval surgeon James Lind, in which sailors received different dietary treatments under otherwise similar conditions, is commonly cited as an early example of controlled clinical comparison. But for roughly two centuries after that, there was no binding, internationally recognized standard governing consent, risk, or oversight in human research — individual investigators and institutions set their own norms, with wide variation and, in the worst cases, none at all.
The clearest illustration of what that absence of oversight allowed is the Tuskegee Syphilis Study (1932-1972), a U.S. Public Health Service study that withheld effective treatment from Black men with syphilis for decades without their informed consent, even after penicillin became the standard cure. Its public exposure in 1972 is the direct proximate cause of the U.S. regulatory framework described later in this guide.
1947 — The Nuremberg Code and the origin of informed consent
The first internationally recognized code of research ethics did not come from a medical or scientific body — it came from a war crimes tribunal. The Nuremberg Code was articulated in the verdict of the U.S. military tribunal in the “Doctors’ Trial” (August 1947), which prosecuted physicians for conducting non-consensual, often fatal experiments on concentration-camp prisoners.
The Code’s first point establishes that the voluntary, informed consent of the human subject is “absolutely essential.” That single sentence is the conceptual origin point for every informed-consent requirement in every research-ethics framework that came after it. The Code carried no independent legal enforcement mechanism, however, and functioned mainly as a moral and historical reference point for roughly two decades before it was elaborated into the frameworks below.
1964 — The Declaration of Helsinki: physician-authored ethical guidance
In 1964, the World Medical Association adopted the Declaration of Helsinki, a statement of ethical principles for medical research involving human subjects, written this time by physicians for physicians rather than emerging from a criminal prosecution. Unlike the Nuremberg Code, the Declaration has been revised multiple times since — most recently in October 2024 — to keep pace with evolving research practice, and it introduced concepts (such as the role of independent ethics review) that later became central to institutional oversight structures. It remains an influential ethical reference internationally, particularly in the framing of placebo-controlled study design and the ethics of withholding treatment from a control arm.
1974 — Tuskegee’s exposure and the National Research Act
Public exposure of the Tuskegee Syphilis Study in 1972 produced rapid legislative consequences in the United States. Congress passed the National Research Act of 1974 (Public Law 93-348, signed July 12, 1974), which created the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research and, for the first time in U.S. law, mandated Institutional Review Board review of federally funded human-subjects research. This is the direct legislative bridge between a specific documented abuse and the review infrastructure every U.S. institution now operates under.
1979 — The Belmont Report and the Common Rule
The Commission created by the National Research Act published its findings in 1979 as the Belmont Report, which articulated three foundational ethical principles for human-subjects research — respect for persons, beneficence, and justice — and distinguished research from ordinary clinical practice. Those three principles were subsequently codified into federal regulation as the Common Rule (45 CFR 46), which remains the baseline human-subjects-protection regulation for federally funded research in the United States today, underpinning informed consent requirements and research ethics committee review structures.
Together, the Nuremberg Code, Declaration of Helsinki, and Belmont Report form the ethical lineage; the National Research Act and Common Rule form the U.S. regulatory lineage built on top of it. Most subsequent international frameworks — including the one described next — assume this ethical baseline and build operational and quality infrastructure around it.
1990s — ICH and the harmonization of Good Clinical Practice
Ethical principles alone do not tell a multinational drug sponsor how to design, monitor, document, and report a trial in a way regulators in different countries will all accept. That operational gap was addressed by the International Council for Harmonisation (ICH), created in April 1990 (originally as the International Conference on Harmonisation) by regulatory authorities and pharmaceutical industry associations from the United States, European Union, and Japan, later expanded to a broader global membership.
ICH’s E6 guideline, first finalized in the mid-1990s and known as ICH GCP (Good Clinical Practice), became the internationally harmonized standard for designing, conducting, recording, and reporting trials involving human subjects. It translated the ethical principles established by the frameworks above into concrete operational requirements: protocol adherence, monitoring, essential document maintenance, investigator responsibilities, and data integrity. The most recent full revision, ICH E6(R3), was finalized in January 2025, with major regulators including the EMA adopting it through 2025; it places explicit new emphasis on quality-by-design and proportionate, risk-based oversight rather than uniform maximal monitoring of every trial.
2010s-2020s — risk-based monitoring and decentralized trials
The most recent phase of this evolution is less about new ethical principles and more about how existing principles are operationalized at scale, using technology and a more proportionate approach to oversight. Two developments are most significant for a research administrator working today:
- Risk-Based Monitoring (RBM) shifts trial monitoring away from a uniform schedule of 100% source-data verification at every site, toward monitoring intensity calibrated to each trial and site’s actual risk profile — a direct expression of the quality-by-design emphasis that ICH E6(R2) and E6(R3) formalized.
- Decentralized Clinical Trials (DCTs) relocate some or all trial activities away from a traditional investigator site — to a participant’s home, a local clinic, or a telehealth visit — using tools such as electronic informed consent and remote data capture, under FDA final guidance on conducting trials with decentralized elements.
Both developments still operate entirely within the ethical baseline set by the Belmont Report and the operational baseline set by ICH GCP — they change how oversight and data collection are executed, not the underlying principles that justify them.
Why this history matters for research administrators today
This is not purely academic context. Specific, everyday research-administration requirements map directly onto specific points in this timeline:
- The informed consent form a participant signs today exists because of the Nuremberg Code’s first point and its elaboration through Belmont and the Common Rule.
- The IRB or REC review that must occur before a federally funded study enrolls its first subject exists because of the National Research Act of 1974, passed in direct response to Tuskegee.
- The monitoring plan, essential documents, and audit trail a sponsor or CRO maintains exist because ICH GCP operationalized the ethical principles into an auditable process.
- The move toward risk-based, proportionate monitoring and decentralized trial elements reflects the field applying those same decades-old principles more efficiently, not abandoning them.
Understanding this lineage helps a research administrator explain compliance requirements to investigators and sponsors as a coherent system with a clear rationale, rather than an arbitrary checklist.
Frequently asked questions
What is generally considered the first controlled clinical trial?
James Lind’s 1747 scurvy trial, which compared different dietary treatments among sailors under broadly similar conditions, is commonly cited as an early example of controlled clinical comparison, though it predates any of the ethical or regulatory frameworks in this guide by roughly two centuries.
What is the difference between the Nuremberg Code and the Declaration of Helsinki?
The Nuremberg Code (1947) emerged from a war-crimes tribunal verdict and is a fixed, ten-point historical document that has never been revised. The Declaration of Helsinki (1964) was written by the World Medical Association specifically as ongoing ethical guidance for physician-researchers and has been revised repeatedly since, most recently in October 2024.
How did the Tuskegee Syphilis Study change U.S. research regulation?
Its public exposure in 1972 led directly to the National Research Act of 1974, which created the commission that produced the Belmont Report and, for the first time, mandated IRB review of federally funded human-subjects research in the United States.
What did ICH GCP add that the Belmont Report and Declaration of Helsinki did not cover?
Belmont and Helsinki establish ethical principles — respect for persons, beneficence, justice, informed consent. ICH GCP translates those principles into concrete operational requirements for how a trial must be designed, monitored, documented, and reported, so that a trial run to standard produces data regulators in multiple jurisdictions can accept.
Are decentralized clinical trials and risk-based monitoring a break from earlier ethical standards?
No. Both operate within the ethical baseline set by the Belmont Report and the operational baseline set by ICH GCP. They change the mechanics of how oversight and data collection happen — for example, calibrating monitoring intensity to actual risk, or moving some visits to a participant’s home — without changing the underlying principles that justify oversight in the first place.
